[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585318":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":18,"centralContacts":32,"locations":18,"responsibleParty":42,"collaborators":18,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":18,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":75,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":18},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Low Adherence Cluster - Intervention Group","EXPERIMENTAL","Dashboard interventions integrated into pharmacist-led education in the low adherence cluster",[13],"Device: interactive visualization dashboard (the Enhancing Sacubitril\u002Fvalsartan Adherence from Initiation to Continuation [ESAIC] dashboard)",{"label":15,"type":16,"description":17,"interventionNames":18},"Low Adherence Cluster - Control Group","NO_INTERVENTION","Pragmatic pharmacist-led education, without dashboard interventions, in the low adherence cluster",null,{"label":20,"type":10,"description":21,"interventionNames":22},"High Adherence Cluster - Intervention Group","Dashboard interventions integrated into pharmacist-led education in the high adherence cluster",[13],{"label":24,"type":16,"description":25,"interventionNames":18},"High Adherence Cluster - Control Group","Pragmatic pharmacist-led education, without dashboard interventions, in the high adherence cluster",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":18},"DEVICE","interactive visualization dashboard (the Enhancing Sacubitril\u002Fvalsartan Adherence from Initiation to Continuation [ESAIC] dashboard)","The dashboard serves as an interactive communication tool during education sessions, promoting real-time dialogue between patients and pharmacists. By collaboratively entering patient-specific data, patients gain insight into personalized visual representations of actionable risk factors. Initially, data specific to the patient are inputted to generate a baseline assessment, presenting hazard ratios that indicate the current condition and pinpoint areas needing improvement. To simulate potential changes, an alternative dataset is deliberately entered, portraying either improvement or deterioration in the patient's status, thereby acting as a motivational tool. Throughout the education session, the dashboard continuously updates hazard ratios, enabling direct comparisons of patient outcomes under varying conditions or treatment scenarios. This dynamic process clearly demonstrates individualized risk-benefit trade-offs in diverse treatment contexts.",[20,9],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Wan-Tseng Hsu, PhD","CONTACT","+886 2 - 3366 - 8195","wantsenghsu@ntu.edu.tw",{"name":39,"role":35,"phone":40,"phoneExt":18,"email":41},"Tung-Chun Russell Chien, PharmD","+886 2 - 3365 - 5365","f12451007@ntu.edu.tw",{"type":43,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100585318","evaluating-dashboard-integrated-pharmacist-led-education-on-improving-sacubitrilvalsartan-adherence-in-heart-failure-pharmd-assist-hfref-100585318",false,"NCT06900803","Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril\u002FValsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)","Pharmacist-Led Education Through Interactive Visualization Dashboards for Adherence Support and Sustained Involvement in Sacubitril\u002FValsartan Therapy for Patients With Heart Failure With Reduced Ejection Fraction (PharmD ASSIST HFrEF): Study Protocol for Implementation in a Parallel-Group, Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* adults aged 20 or older\n* a diagnosis of HFrEF, which is defined by a left ventricular ejection fraction of 40% or less\n* currently receiving sacubitril\u002Fvalsartan at the time of recruitment\n* receiving care at the cardiology department or cardiology ward at National Taiwan University Hospital\n* referral from the clinicians at National Taiwan University Hospital\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement)\n* having received care at the pharmacist-led HF clinic at National Taiwan University Hospital","ALL","20 Years",{"count":54,"type":55},200,"ESTIMATED","INTERVENTIONAL",[58],"NA","The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed sacubitril\u002Fvalsartan. The main question it aims to answer is: Can pharmacist-led interactive visualization dashboards improve adherence to sacubitril\u002Fvalsartan compared to usual care without the dashboard intervention?\n\nResearchers will compare patients receiving pharmacist-led education with interactive dashboards to those receiving standard education, assessing differences in medication adherence and clinical outcomes, among others.\n\nParticipants will:\n\n* Complete baseline and follow-up questionnaires on medication adherence and satisfaction with pharmacist-provided services, and others.\n* Engage in education sessions led by pharmacists, with or without dashboard integration.\n\nThe study outcomes will include medication adherence, and secondary outcomes such as patient satisfaction with pharmacist-provided services, optimized guideline-directed medical therapy score, time to high medication adherence, the calculated proportion of days covered, New York Heart Association functional classification, and the net promoter score used for evaluating recommendation and satisfaction with the dashboard intervention.",[61,62,63],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Sacubitril\u002FValsartan","Medication Adherence",[65,66,67,68,69,70,71,72,73,74],"heart failure with reduced ejection fraction","medication adherence","dashboard","health information technology","patient education","pharmacist","pragmatic trial","randomized controlled trial","sacubitril\u002Fvalsartan","implementation","NOT_YET_RECRUITING","2025-03-27",{"date":78,"type":79},"2025-04-02","ACTUAL",{"date":81,"type":55},"2025-04-07",{"date":83,"type":55},"2027-10-31",{"name":5,"class":6}]